

or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1, which is (*E*)-1-(4-(5-carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-(3-morpholinopropoxy)-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-methoxy-1H-benzo[d]imidazole-5-carboxamide tris hydrochloride, or a tautomer thereof.

6. A pharmaceutical composition comprising the compound, a tautomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate thereof according to any one of claims 1- 5, and a pharmaceutically acceptable excipient.

7. A compound, a tautomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate thereof according to any one of claims 1- 5 for use in therapy.

8. A compound, a tautomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate thereof according to any one of claims 1-5 for use in the treatment of a STING-mediated disease.

9. Use of the compound, a tautomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate thereof according to any one of claims 1-5 in the manufacture of a medicament for the treatment of a STING-mediated disease.

10. The compound or use according to any of claims 7-9, wherein the disease is cancer.

11. The compound or use according to any of claims 7-9, wherein the disease is a solid tumor.

CLAIMS

1. A compound which is (*E*)-1-(4-(5-carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-(3-morpholinopropoxy)-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-methoxy-1H-benzo[d]imidazole-5-carboxamide having the structure of



or a tautomer thereof,
or a pharmaceutically acceptable salt thereof,
or a hydrate thereof.

2. The compound according to claim 1, which is a pharmaceutically acceptable salt of (*E*)-1-(4-(5-carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-(3-morpholinopropoxy)-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-methoxy-1H-benzo[d]imidazole-5-carboxamide,
or a tautomer thereof.

3. The compound according to claim 1, which is (*E*)-1-(4-(5-carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-(3-morpholinopropoxy)-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-methoxy-1H-benzo[d]imidazole-5-carboxamide, or a tautomer thereof.

4. The compound according to claim 1, which is represented by (E)-1-((E)-4-((E)-5-carbamoyl-2-((1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino)-7-(3-morpholinopropoxy)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-((1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino)-7-methoxy-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide having the structure of